Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus
ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.
Pharma & Biotech